proteasome inhibitor

Carfilzomib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

multiple myeloma  

carfilzomib  
ENDEAVOR, 2016          NCTcarfilzomibbortezomibrelapsed MMRisk of bias suggesting-21%-47%
ECOG-ACRIN    NCTcarfilzomibbortezomid -
CLARION    NCTcarfilzomibbortezomid -
ASPIRE, 2014            NCTcarfilzomib lenalidomide dexamethasonelenalidomide and dexamethasone alonerelapsed MMRisk of bias suggesting-21%-31%
FOCUS, 2017        NCTcarfilzomiblow-dose corticosteroids relapsed and refractory multiple myeloma (RRMM)Risk of bias negative-3%